Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of pNGVL4aCRTE6E7L2 and TA-CIN in Persistent HPV16+ ASC-US or LSIL
NCT03913117Phase 1Recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Jul 2023
- Primary completion
- Dec 2027
- Modality
- Therapeutic Vaccines, Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of PVX-4 and TA-CIN in atypical squamous cells of undetermined significance (ASC-US), Squamous Intraepithelial Lesion (SIL) and human papillomavirus infection (4 arms), sponsored by University of Alabama at Birmingham. Primary endpoints: Safety and feasibility of pNGVL4aCRTE6E7L2 DNA vaccination at 12 months, Dose finding at 12 months and 1 more. Started Jul 2023; status: recruiting.
02
Drugs
PVX-4TA-CIN
03
Conditions
atypical squamous cells of undetermined significance (ASC-US)Squamous Intraepithelial Lesion (SIL)human papillomavirus infection
Beyond the preview
Go deeper on NCT03913117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03913117.